TP53 and breast carcinoma: While this exact mutation was not observed in the TCGA breast cohort, a missense mutation was identified at the same position in one case (H168P) [41,42], supporting the likelihood that alteration of TP53 is a founding event critical for the development of basal-like breast cancer [43] and subsequent metastasis.